EZH2 and breast carcinoma: Data shows that Patients with lower EZH2 expression had longer overall survival (OS), recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in total breast cancer dataset (HR = 1.56, p < 0.05; HR = 1.73, p < 0.05; HR = 1.71, p < 0.05).